Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Furosemide
Drug ID BADD_D00979
Description Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative.[L7958] Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure.[L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients.[A182495] The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.[L7958]
Indications and Usage Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.[L7958] Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.[L9659] Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.[L7958]
Marketing Status approved; vet_approved
ATC Code C03CA01
DrugBank ID DB00695
KEGG ID D00331
MeSH ID D005665
PubChem ID 3440
TTD Drug ID D0PQ3G
NDC Product Code 72603-474; 51552-0940; 51927-0077; 53002-4300; 55150-323; 61919-442; 63323-280; 63629-1120; 0378-0208; 0404-9864; 68083-432; 68083-433; 68083-434; 0409-6102; 70121-1076; 70860-302; 70934-737; 71335-0384; 71872-7236; 0615-8369; 0904-7177; 36000-063; 43063-849; 51655-310; 55154-9582; 66432-549; 67296-1469; 68071-1708; 68071-1809; 68071-4445; 69315-118; 70756-619; 72789-032; 63415-0025; 43063-806; 43353-747; 43547-402; 51079-073; 51662-1572; 60760-708; 63187-097; 63187-437; 63187-739; 69844-051; 70518-0050; 70518-0251; 70756-620; 70934-111; 0054-4297; 0054-4301; 0054-8297; 71872-7295; 60760-707; 63187-517; 63629-1216; 0378-0232; 64980-564; 67296-1547; 68071-3461; 68788-7354; 69315-116; 0054-3294; 71335-0842; 71335-1632; 0054-8299; 71610-636; 71872-7277; 72789-033; 72789-157; 42291-468; 42708-174; 43353-018; 43353-341; 43547-401; 50090-2560; 51407-113; 51407-114; 51662-1336; 52584-284; 63629-1119; 63629-1217; 64980-562; 0404-9863; 68094-756; 68094-867; 69315-117; 69844-052; 70121-1163; 70529-550; 71335-0397; 71872-7278; 49452-3222; 57451-0007; 36000-283; 43353-069; 50090-5429; 51655-481; 51662-1226; 51662-1574; 58118-0143; 60760-858; 70121-1164; 70518-0809; 70518-2766; 70529-061; 0054-3298; 72789-030; 48087-0053; 51927-1784; 71052-238; 30698-060; 30698-067; 36000-282; 60760-217; 61919-255; 63629-1215; 0378-0216; 64679-759; 68071-2313; 68071-3273; 70518-0836; 70529-062; 70529-549; 0054-8301; 71610-096; 71610-635; 0615-8370; 72603-251; 83284-002; 16729-500; 25021-311; 36000-284; 43547-403; 50090-5702; 50090-6219; 50090-6221; 51662-1227; 63187-506; 68071-4022; 71610-049; 17337-0087; 72166-003; 16729-502; 23155-473; 42708-123; 43063-702; 50090-3313; 50090-3338; 51079-072; 51079-527; 51407-115; 52584-283; 55150-322; 55150-324; 55154-2365; 63187-790; 63629-1214; 66432-550; 68071-3459; 68788-6784; 70518-3757; 70756-618; 0054-4299; 71288-203; 71335-0601; 71610-634; 71872-7127; 72572-190; 0904-7178; 57451-0006; 66326-401; 70193-0002; 42291-469; 53808-1109; 55154-4452; 55154-9581; 55700-452; 61919-242; 64980-563; 0404-9862; 0409-1639; 68788-6948; 68788-7265; 69844-053; 70518-3061; 71335-0852; 71610-284; 71872-7059; 0615-8368; 72603-133; 81565-201; 48087-0054; 51927-0078; 82348-105; 16729-501; 17224-178; 30698-066; 36000-064; 36000-065; 42291-470; 43063-716; 50090-3339; 51662-1575; 55154-2364; 55700-461
UNII 7LXU5N7ZO5
Synonyms Furosemide | Frusemide | Fursemide | Frusemid | Fusid | Lasix | Furosemide Monohydrochloride | Errolon | Furanthril | Furantral | Furosemide Monosodium Salt
Chemical Information
Molecular Formula C12H11ClN2O5S
CAS Registry Number 54-31-9
SMILES C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory symptom22.12.02.0130.000014%-
Sinus node dysfunction02.03.03.0170.000014%
Multiple organ dysfunction syndrome08.01.03.0570.000153%
Adenocarcinoma gastric07.21.02.002; 16.13.03.0020.000014%-
Cardiac failure chronic02.05.01.0090.000035%-
Cerebellar haemorrhage17.08.01.046; 24.07.04.0230.000014%-
Concomitant disease aggravated08.01.03.0630.000042%-
Confabulation19.10.03.0090.000035%-
Cyanosis central02.11.04.005; 22.02.02.0120.000014%-
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000021%-
Hyperaldosteronism05.01.01.006; 14.05.04.006; 24.08.04.0050.000021%-
Hyponatraemic syndrome14.05.04.0090.000090%-
Metastases to pleura16.22.02.022; 22.05.04.0020.000014%-
Renal atrophy20.01.06.0010.000028%-
Thyrotoxic periodic paralysis05.02.02.005; 14.11.01.045; 17.01.04.0210.000014%-
Vitamin B1 deficiency14.12.02.0120.000111%-
Wernicke's encephalopathy14.12.02.013; 17.13.01.0130.000028%-
Shoshin beriberi02.05.03.006; 14.12.02.0100.000028%-
Silent myocardial infarction02.02.02.022; 24.04.04.0250.000014%-
Intracranial hypotension12.01.10.008; 17.02.05.0360.000028%-
Small intestinal haemorrhage07.12.03.002; 24.07.02.0190.000014%
Lymphangiosis carcinomatosa01.09.01.027; 16.22.02.009; 24.09.02.0070.000014%-
Non-alcoholic steatohepatitis09.01.07.035; 14.08.04.0240.000014%-
Gastrointestinal tract mucosal pigmentation07.11.03.0090.000042%-
Cell death08.03.03.003; 14.11.02.0050.000014%-
Nephrogenic anaemia01.03.04.001; 20.01.01.0070.000014%-
Parakeratosis23.03.03.0670.000014%-
Sopor17.02.04.021; 19.02.04.0020.000153%-
Acquired macroglossia07.14.01.0090.000035%-
Renal cyst haemorrhage16.27.01.005; 20.01.04.017; 24.07.07.0030.000014%-
The 18th Page    First    Pre   18 19    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene